Key points are not available for this paper at this time.
Abstract Background: Although several gene expression-based assays are validated for informing prognosis and treatment decision-making for breast cancer (BC) patients, their uptake has been hampered by technical complexities and cost, particularly in underrepresented and low-resource settings. Here, we explored whether machine learning-based features on standard hematoxylin and eosin (H0.0001), and according to RS categories within both ER+ (P=0.009) and ER- (P=0.006) BC subtypes in the validation set. Conclusion: H 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C022.
Building similarity graph...
Analyzing shared references across papers
Loading...
Mustapha Abubakar
Amber N. Hurson
Thomas U. Ahearn
Cancer Epidemiology Biomarkers & Prevention
University of North Carolina at Chapel Hill
National Cancer Institute
University of Calgary
Building similarity graph...
Analyzing shared references across papers
Loading...
Abubakar et al. (Sat,) studied this question.
www.synapsesocial.com/papers/68e57c1db6db64358751b48e — DOI: https://doi.org/10.1158/1538-7755.disp24-c022